In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their success in managing blood sugar levels and drastically reducing weight. Between new clinical trial results and a boom in celebrity usage, the popularity of the medications increased drastically over the past two years.

GLP-1 medications—like Ozempic, Wegovy, and Zepbound—can help you shed pounds, but only if taken properly. Don't get caught making these semaglutide slip-ups.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

What’s better for kidneys: bariatric surgery or diabetes medication? Find out how weight-loss surgery stacks up against GLP-1 drugs in fighting kidney disease.

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, people who had been taking weekly semaglutide 2.4 mg (Wegovy) along with a lifestyle intervention regained two-thirds of the weight they had lost a year after coming off the drug.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 drugs when it comes to preserving kidney function, a new study finds.

New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.